Vestal Point Capital LP Invests $14.25 Million in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Vestal Point Capital LP bought a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 20,000 shares of the biopharmaceutical company's stock, valued at approximately $14,247,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Willner & Heller LLC lifted its position in Regeneron Pharmaceuticals by 3.9% in the fourth quarter. Willner & Heller LLC now owns 399 shares of the biopharmaceutical company's stock valued at $284,000 after purchasing an additional 15 shares during the last quarter. OLD Second National Bank of Aurora grew its stake in Regeneron Pharmaceuticals by 0.5% in the fourth quarter. OLD Second National Bank of Aurora now owns 2,843 shares of the biopharmaceutical company's stock worth $2,025,000 after purchasing an additional 15 shares during the period. Rakuten Securities Inc. grew its stake in shares of Regeneron Pharmaceuticals by 62.5% in the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 15 shares during the last quarter. TD Private Client Wealth LLC grew its stake in shares of Regeneron Pharmaceuticals by 9.6% in the fourth quarter. TD Private Client Wealth LLC now owns 171 shares of the biopharmaceutical company's stock worth $122,000 after acquiring an additional 15 shares during the last quarter. Finally, Manchester Capital Management LLC grew its stake in shares of Regeneron Pharmaceuticals by 12.6% in the fourth quarter. Manchester Capital Management LLC now owns 161 shares of the biopharmaceutical company's stock worth $115,000 after acquiring an additional 18 shares during the last quarter. Institutional investors own 83.31% of the company's stock.

Analyst Upgrades and Downgrades

REGN has been the topic of a number of research analyst reports. The Goldman Sachs Group lowered their price target on Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating on the stock in a report on Wednesday, April 30th. Wells Fargo & Company decreased their price objective on Regeneron Pharmaceuticals from $750.00 to $700.00 and set an "overweight" rating on the stock in a research note on Wednesday, April 30th. StockNews.com downgraded Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Thursday, May 1st. TD Cowen decreased their target price on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a "buy" rating on the stock in a research note on Tuesday, February 4th. Finally, Canaccord Genuity Group raised Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, April 22nd. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, nineteen have issued a buy rating and three have issued a strong buy rating to the company's stock. According to data from MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus price target of $890.60.

Regeneron Pharmaceuticals Trading Down 1.7%

Shares of Regeneron Pharmaceuticals stock traded down $10.17 on Wednesday, reaching $604.62. The company had a trading volume of 1,089,118 shares, compared to its average volume of 795,612. The firm's 50-day moving average price is $595.54 and its two-hundred day moving average price is $679.20. Regeneron Pharmaceuticals, Inc. has a 1 year low of $520.50 and a 1 year high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The firm has a market cap of $65.28 billion, a price-to-earnings ratio of 15.79, a P/E/G ratio of 2.34 and a beta of 0.43.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business had revenue of $3.03 billion for the quarter, compared to analysts' expectations of $3.40 billion. During the same quarter in the previous year, the firm earned $9.55 EPS. Regeneron Pharmaceuticals's revenue was down 3.7% compared to the same quarter last year. As a group, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th will be issued a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 0.58%. The ex-dividend date of this dividend is Tuesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio is 8.96%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.